Study guide
16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials
Board Certified Specialist in Renal Nutrition CSR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Kidney Disease Foundations
1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk
2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment
2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry
3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools
3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss
4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History
4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment
5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality
5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment
6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning
6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances
7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients
7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy
8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy
8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients
9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD
10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support
10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support
11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities
11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories
13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics
13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence
14 Chapter 14: Domain 2 — Care Coordination, Communication & Education
14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support
15 Chapter 15: Domain 3 — Regulations & Quality Management
15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool
16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials
Key Takeaways Explain This Topic AI
Randomized controlled trials test cause and effect; cohort and case-control studies show associations that can reflect confounding or reverse causation.
A ratio (relative risk, odds ratio or hazard ratio) is statistically significant at the 95% level only when its confidence interval excludes 1.0.
The number needed to treat is 1 divided by the absolute risk reduction: a fall in event rate from 20% to 15% gives an ARR of 5% and an NNT of 20.
The HEMO trial found no survival benefit from a higher hemodialysis dose or high-flux membranes, and ADEMEX found no survival benefit from increasing PD small-solute clearance.
CHOIR and TREAT showed that targeting normal hemoglobin with ESAs raised cardiovascular risk (TREAT: stroke hazard ratio 1.92), which shaped the current Hb targets.
Last updated: September 2026
Why research appraisal is on the exam
The CSR outline's Domain 3 includes current research, clinical practices and protocols . A specialist must read new evidence critically, explain it to patients and colleagues, and decide whether it should change practice. Exam items may give a study summary and ask what the results show, or ask why a guideline grades a statement as weak.
The evidence hierarchy
From strongest to weakest for questions about treatment effects:
- Systematic reviews and meta-analyses of randomized controlled trials (RCTs)
- Individual RCTs
- Cohort studies , prospective or retrospective
- Case-control studies
- Cross-sectional studies (a snapshot of exposure and outcome together)
- Case series and case reports
- Expert opinion , including guideline OPINION statements and practice points
GRADE starts RCT evidence at "high" and observational evidence at "low." It then downgrades for risk of bias, inconsistency, indirectness, imprecision or publication bias, and can upgrade observational evidence for large effects or a dose-response. This is why so many nutrition statements in KDOQI 2020 are graded C or D, or given as OPINION.
Designs and what they can show
Design Strength Typical limitation in renal nutrition
RCT Randomization balances known and unknown confounders, so it can show causation Short, small nutrition trials; poor adherence; hard to blind diet
Cohort Follows exposed and unexposed people over time; good for rare exposures and many outcomes Confounding and reverse causation
- Case-control Efficient for rare outcomes Recall bias; choice of controls
- Cross-sectional Quick prevalence estimates Cannot tell which came first
Diagnostic accuracy studies compare a tool, such as a PEW screen, with a reference standard. They report sensitivity (the share of true cases the tool detects), specificity (the share of non-cases it correctly clears) and predictive values. A highly sensitive screen is best for ruling a condition out.
Bias and confounding in nephrology nutrition research
Confounding: a third factor linked to both exposure and outcome. Sicker patients eat less and die sooner, so low intake looks lethal even if illness is the true cause.
Reverse causation: the outcome process causes the "exposure." The obesity paradox in hemodialysis (higher BMI linked to lower mortality) may partly reflect wasting from illness lowering BMI before death. It is an observational association, and KDOQI 2020 accordingly grades the BMI-mortality statements as prognostic, not as a reason to promote weight gain.
Selection and survivor bias: prevalent dialysis cohorts include only people who survived long enough to be counted.
Measurement bias: albumin assays (BCG versus BCP) differ; food records underreport; nPCR reflects catabolism, not intake, in unstable patients.
Attrition bias: dropouts in diet trials are often the sickest patients.
Intention-to-treat versus per-protocol: intention-to-treat analysis keeps everyone in their randomized group and protects randomization. Per-protocol analysis can overstate benefit.
Reading the numbers
Relative risk (RR) or hazard ratio (HR): below 1.0 means lower risk in the intervention group and above 1.0 means higher risk. An HR describes risk over time (from survival analysis).
Odds ratio (OR): common in case-control studies. It approximates RR when outcomes are rare.
95% confidence interval (CI): the range of plausible true values. For ratios, a CI that includes 1.0 is not statistically significant. For differences, a CI that includes 0 is not significant.
p-value: the probability of results at least this extreme if there were truly no effect. p < 0.05 is conventional, but it does not measure how large or important the effect is.
Absolute risk reduction (ARR): control event rate minus intervention event rate.
Number needed to treat (NNT): NNT = 1 ARR \text{NNT} = \frac{1}{\text{ARR}} NNT = ARR 1 (with the ARR written as a proportion).
Worked example. In a hypothetical trial, 20% of control patients and 15% of treated patients were hospitalized in a year. ARR = 0.20 − 0.15 = 0.05 , NNT = 1 0.05 = 20 , RR = 0.15 0.20 = 0.75 \text{ARR} = 0.20 - 0.15 = 0.05, \quad \text{NNT} = \frac{1}{0.05} = 20, \quad \text{RR} = \frac{0.15}{0.20} = 0.75 ARR = 0.20 − 0.15 = 0.05 , NNT = 0.05 1 = 20 , RR = 0.20 0.15 = 0.75
Twenty patients must be treated for a year to prevent one hospitalization. The relative risk reduction (25%) sounds larger than the absolute benefit (5 percentage points), so always look for both.
Statistical versus clinical significance. A large trial can find a statistically significant 0.1 g/dL albumin change that makes no clinical difference. A small trial can miss a real benefit because it is underpowered (a type II error).
Landmark trials that shaped renal nutrition and dialysis practice
Trial (year) Question Main finding
MDRD (1994) Protein restriction and BP targets in non-diabetic CKD The primary analysis did not show a significant slowing of GFR decline; later analyses and meta-analyses informed today's supervised low-protein recommendations
HEMO (2002) Higher versus standard HD dose, and high- versus low-flux membranes No mortality benefit from either
ADEMEX (2002) Higher peritoneal small-solute clearance No survival benefit ; this supported the weekly Kt/V minimum of 1.7
CHOIR (2006), CREATE (2006), TREAT (2009) Normal versus lower hemoglobin targets with ESAs Higher targets gave no benefit and more harm; TREAT showed about double the stroke risk (HR 1.92) with darbepoetin targeting 13 g/dL
PIVOTAL (2019) Proactive high-dose versus reactive low-dose IV iron in HD Proactive iron (held at ferritin above 700 ng/mL or TSAT of 40% or more) was non-inferior for major cardiovascular events and death, lowered ESA doses and reduced transfusions
DAPA-CKD (2020), EMPA-KIDNEY (2023) SGLT2 inhibitors in CKD Slowed kidney disease progression across diabetic and non-diabetic CKD
FLOW (2024) Semaglutide in type 2 diabetes with CKD Fewer major kidney outcome events
Two lessons run through these trials. First, intuitive biomarker targets can mislead : pushing hemoglobin, Kt/V or small-solute clearance higher did not improve survival. Second, observational associations need trial testing before they become practice.
Evaluating a new article: a quick checklist
Question: population, intervention, comparison, outcome (PICO). Is it relevant to your patients?
Design: is it the right design for the question, and was allocation randomized and concealed?
Bias: blinding, follow-up completeness, intention-to-treat, funding and conflicts of interest.
Results: effect size with CI, absolute as well as relative effects, and patient-important outcomes (death, hospitalization, quality of life) rather than surrogates alone.
Applicability: do the participants resemble your patients (dialysis modality, diabetes, age)? Are harms and costs acceptable?
Fit with guidelines: does it confirm, refine or conflict with KDOQI or KDIGO? One study rarely overturns a guideline.